Humacyte said yesterday that it started a phase II trial of its human acellular vessel, Humacyl, as an artificial bypass graft in patients with peripheral arterial disease. The non-randomized trial is slated to enroll 20 patients over the next year. Humacyl will be surgically implanted above the knee in the legs of PAD patients in […]
Humacyte is launching a Phase III study of its lab-grown blood vessel Humacyl in 350 patients with end-stage renal disease who are on hemodialysis and don’t qualify for a standard surgical treatment, and Boston’s Brigham & Women’s Hospital plans to take part. Plans to move ahead to Phase III follow a promising Phase II clinical study […]
Humacyte said today that it raised a $150 million Series B round it plans to use to back a Phase III trial of its Humacyl lab-grown blood vessel technology. Research Triangle Park, N.C.-based Humacyte, which raised a $12 million Series A round back in 2010, uses a proprietary technology to engineer human tissues that can be shaped […]
Duke University spin-off Humacyte Inc. landed a $12 million investment and pharmaceutical industry veteran Carrie Cox for CEO.
The Durham, N.C.-based regenerative medicine company recently raised $12 million from a single investor through a debt offering, according to an amended filing with the Securities & Exchange Commission. Another amended filing shows the company raised $7 million in debt about a year ago.